Johnson & Johnson to Acquire Proteologix
Johnson & Johnson has entered into a definitive agreement to acquire Proteologix, a Redwood City, California-based biotechnology company specializing in bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for additional milestone payments. The transaction is expected to close by mid-year 2024, pending antitrust clearance and other customary closing conditions. Proteologix’s … Read more